The results showed that AS-IV improved the symptoms of HFpEF mice mainly in improving myocardial hypertrophy, pulmonary congestion, reducing SBP, DBP and ANP, NT-proBNP, and obesity and dyslipidemia. This evidence concerns the gene NPPA and obesity disorder.